Regeneron & Sanofi discuss expanding partnership, potentially including Dupixent follow-ons. CEOs Schleifer & Garijo cite need to rebuild trust amid ongoing litigation.
Regeneron and Sanofi said they are in the early stages of discussing areas for further collaboration, building on one of the most fruitful pharmaceutical company …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
Sanofi: Belén Garijo setzt auf Innovation und Wachstum
A series of label expansions for Sanofi and Regeneron’s Dupixent, including its key 2024 FDA
Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two…
After losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator.
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a…
Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on…
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for…
